MARKET

ACRS

ACRS

Aclaris
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.780
-0.030
-1.66%
Closed 16:00 11/13 EST
OPEN
1.770
PREV CLOSE
1.810
HIGH
1.810
LOW
1.720
VOLUME
336.65K
TURNOVER
--
52 WEEK HIGH
9.85
52 WEEK LOW
0.7400
MARKET CAP
73.67M
P/E (TTM)
-0.4270
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ACRS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ACRS News

  • Aclaris Therapeutics to Present at Upcoming Investor Conferences
  • GlobeNewswire.1d ago
  • Aclaris Therapeutics, Inc. (ACRS) CEO Neal Walker on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.3d ago
  • Edited Transcript of ACRS earnings conference call or presentation 7-Nov-19 10:00pm GMT
  • Thomson Reuters StreetEvents.5d ago
  • Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs
  • GlobeNewswire.6d ago

More

Industry

Biotechnology & Medical Research
+0.42%
Pharmaceuticals & Medical Research
+0.16%

Hot Stocks

Name
Price
%Change

About ACRS

Aclaris Therapeutics, Inc. is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. The Company’s drug discovery platform KINect technology is a kinase-focused drug discovery engine utilizing computational chemistry to integrate proprietary compound collections and highly experienced biologists and medicinal chemists to identify and advance potential candidates into preclinical and clinical development.
More

Webull offers Aclaris Therapeutics Inc (ACRS) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.